Shares of Medivation, Inc. MDVN hit a 52-week high of $80.99 on Thursday ... The cash nature deal is a huge boost for the stock as well as Medivation’s cash position, thereby delivering significant and immediate value to shareholders.
MDVN’s niche is research into other diseases for which few treatment options exist, but none of this new research is close enough to warrant owning the stock at $129 a share. Well, yipsee doodle dandy, I like your selection of Universal …
Today, the stock is almost $1,500 per share! That works out to an average compound annual return of about 50% per year. There are only two stocks in my universe that can claim a better record than that. One is Medivation (MDVN) and the …
(Continued from Prior Part) Is Medivation fairly valued on an EV-to-EBITDA basis? On April 11, 2016, pharmaceutical company Medivation (MDVN) was trading at a forward ... stocks while Medivation is a growth stock. Medivation’s …
Right now, I'm focusing on a biotech stock I first discussed in October 2011. Back then, I profiled three oncology stocks that had major upside. How have they done? Well, Medivation (Nasdaq: MDVN) and Threshold Pharmaceuticals …
Since the expansion of the drug was approved, Medivation’s stock has increased about 60% and they raked ... Zytiga and Medivation’s (NASDAQ: MDVN) Xtandi. Xu gave Takai an Outperform rating and a $44 price target. Xu acknowledged …
(Continued from Prior Part) Biotech stock performances By market cap ... Among the mid-caps, Medivation (MDVN) fell by 9.25%, as JMP Securities lowered MDVN’s 2015 and 2016 earnings. The impact was less compared to BIIB, as IBB …
"(Sanofi's) research and development track record is not great, and it is guiding for no meaningful earnings per share growth in 2016/2017," said Anderson, who downgraded the stock to market-perform in November.